a non-viral gene therapy platform to treat pathologic inflammation through immune modulation.
The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system.
Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene t...
a non-viral gene therapy platform to treat pathologic inflammation through immune modulation.
The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system.
Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10 to addresses pathologic inflammation and pain.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.